Aydin Huseynov

Graig Suvannavejh

Jeffrey Jones

Jiale Song

Li Wang Watsek

Xun Lee

Craig Suvanevej

Jeff Jones

Li Watsek

Roger Song

- Corvus Pharmaceuticals (CRVS) announced the presentation of **interim data** from its Phase 1b/2 clinical trial of **ciforadenant** for metastatic renal cell cancer (RCC) at the European Society for Medical Oncology (ESMO) Congress 2025 on **October 17, 2025**.  **[1626971_20b95e273fce44cd84696f9d88bc5a26_0]** 
- The triplet therapy, combining ciforadenant with ipilimumab and nivolumab, was found to be **feasible and well tolerated** in patients with unfavorable disease characteristics.  **[1626971_20b95e273fce44cd84696f9d88bc5a26_0]** **[1626971_20b95e273fce44cd84696f9d88bc5a26_1]** 
- As of May 2025, the trial demonstrated a **deep response rate of 34%**, an **objective response rate (ORR) of 46%** (including two complete responses and 21 partial responses), and a median progression-free survival (PFS) of **11.04 months**.  **[1626971_20b95e273fce44cd84696f9d88bc5a26_1]** 
- The **34% deep response rate** shows an improvement compared to historical data of 32% for the doublet therapy alone, though it is not yet statistically significant.  **[1626971_20b95e273fce44cd84696f9d88bc5a26_1]** 
- **Nineteen patients remain on therapy** for longer follow-up to further assess the potential benefits of blocking adenosine signaling with ciforadenant.  **[1626971_20b95e273fce44cd84696f9d88bc5a26_0]** **[1626971_20b95e273fce44cd84696f9d88bc5a26_1]**

Corvus Pharmaceuticals Presents Interim Phase 1b/2 Clinical Trial Data for Ciforadenant in Metastatic RCC